SARS-CoV-2 VLP Vaccine
The extremely attenuated vaccinia strain known as the “modified vaccinia virus Ankara strain” was acquired by humans during the search for a vaccinia virus to use as a smallpox vaccine. Following MVA infection, the genome depends on its promoter and transcription machinery in the cytoplasm to finish gene replication and expression rather than entering the nucleus. Six significant gene segments were lost by MVA during the passaging process. The ability of the virus to infect and express itself is unaffected by the insertion of foreign genes, which can be inserted into these sections in amounts more than 25 kb. In the 1970s, more than 120,000 people received vaccinations against a smallpox vaccine strain.
For more: COVID-19 VLP Vaccine with MVA Vector
